他汀类药物与内科ICU谵妄风险的相关性
该研究为回顾性倾向匹配队列分析,纳入2012年9月1日至2015年9月30日Hartford Hospital内科ICU住院患者,初始10216例次经Confusion Assessment Method筛查谵妄,排除后6664例用于匹配他汀使用者与非使用者,倾向匹配队列为1475例他汀使用者按1:1匹配对照。谵妄定义为Confusion Assessment Method评估阳性,为主要终点。未匹配队列谵妄患病率22.3%,倾向匹配队列22.8%。他汀使用与谵妄风险显著降低相关(OR 0.47;95%CI 0.38-0.56);按他汀类型,阿托伐他汀(OR 0.51;95%CI 0.41-0.64)、普伐他汀(OR 0.40;95%CI 0.28-0.58)和辛伐他汀(OR 0.33;95%CI 0.21-0.52)均与谵妄频率降低显著相关。作者结论认为他汀使用与住院患者谵妄风险降低独立相关,并建议随机试验验证不同他汀类型对谵妄的保护作用。
要点
- 在倾向匹配的内科ICU住院患者中,他汀使用与谵妄风险降低独立相关(OR 0.47;95%CI 0.38-0.56)。
- 按他汀类型,阿托伐他汀(OR 0.51;95%CI 0.41-0.64)、普伐他汀(OR 0.40;95%CI 0.28-0.58)、辛伐他汀(OR 0.33;95%CI 0.21-0.52)均与谵妄频率降低显著相关。
- 未匹配队列谵妄患病率为22.3%,倾向匹配队列为22.8%,谵妄定义均为Confusion Assessment Method评估阳性。
- 该研究为回顾性倾向匹配队列分析,作者建议开展随机试验验证不同他汀类型对谵妄的保护作用。
适用人群与场景
- 纳入2012年9月1日至2015年9月30日于Hartford Hospital内科ICU住院的患者,初始10216例次经Confusion Assessment Method筛查谵妄,排除后6664例用于匹配他汀使用者与非使用者,倾向匹配队列为1475例他汀使用者按1:1匹配对照。
- 研究场所为内科ICU住院场景。
诊断标准与关键阈值
- 谵妄定义为Confusion Assessment Method评估阳性。
研究设计与关键结果
- 研究类型为回顾性倾向匹配队列分析,样本量倾向匹配队列1475例他汀使用者按1:1匹配对照,人群为内科ICU住院患者,干预为无,主要终点为Confusion Assessment Method评估阳性的谵妄。
- 未匹配队列谵妄患病率22.3%,倾向匹配队列谵妄患病率22.8%。
- 他汀使用与谵妄风险显著降低相关(OR 0.47;95%CI 0.38-0.56)。
- 阿托伐他汀与谵妄频率降低显著相关(OR 0.51;95%CI 0.41-0.64)。
- 普伐他汀与谵妄频率降低显著相关(OR 0.40;95%CI 0.28-0.58)。
- 辛伐他汀与谵妄频率降低显著相关(OR 0.33;95%CI 0.21-0.52)。
证据类型、等级与局限
- 证据类型为回顾性倾向匹配队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为他汀使用与住院患者谵妄风险降低独立相关,按他汀类型阿托伐他汀、普伐他汀和辛伐他汀使用者中该降低显著。
- 作者建议开展随机试验验证不同他汀类型对谵妄的保护作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To examine the association between statin use and the risk of delirium in hospitalized patients with an admission to the medical ICU.
DESIGN: Retrospective propensity-matched cohort analysis with accrual from September 1, 2012, to September 30, 2015.
SETTING: Hartford Hospital, Hartford, CT.
PATIENTS: An initial population of patients with an admission to a medical ICU totaling 10,216 visits were screened for delirium by means of the Confusion Assessment Method. After exclusions, a population of 6,664 was used to match statin users and nonstatin users. The propensity-matched cohort resulted in a sample of 1,475 patients receiving statin matched 1:1 with control patients not using statin.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Delirium defined as a positive Confusion Assessment Method assessment was the primary end point. The prevalence of delirium was 22.3% in the unmatched cohort and 22.8% in the propensity-matched cohort. Statin use was associated with a significant decrease in the risk of delirium (odds ratio, 0.47; 95% CI, 0.38-0.56). Considering the type of statin used, atorvastatin (0.51; 0.41-0.64), pravastatin (0.40; 0.28-0.58), and simvastatin (0.33; 0.21-0.52) were all significantly associated with a reduced frequency of delirium.
CONCLUSIONS: The use of statins was independently associated with a reduction in the risk of delirium in hospitalized patients. When considering types of statins used, this reduction was significant in patients using atorvastatin, pravastatin, and simvastatin. Randomized trials of various statin types in hospitalized patients prone to delirium should validate their use in protection from delirium.
参考来源
- Mather JF, Corradi JP, Waszynski C, et al. Statin and Its Association With Delirium in the Medical ICU. Crit Care Med. 2017. PMID: 28622167. doi:10.1097/CCM.0000000000002530
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。